Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2011 2
2013 3
2014 2
2015 6
2016 3
2017 6
2018 3
2019 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics, the Immunological Impact, and the Effect on HIV Ex-Vivo Infectivity of Maraviroc, Raltegravir, and Lopinavir in Men Who Have Sex with Men Using Postexposure Prophylaxis.
Leal L, Guardo AC, Bedoya LM, Rodríguez de Miguel C, Climent N, Rovira C, Beltrán M, Llach J, Alcamí J, Kashuba ADM, Gatell JM, Plana M, García F. Leal L, et al. Among authors: guardo ac. AIDS Res Hum Retroviruses. 2023 May;39(5):211-221. doi: 10.1089/AID.2021.0232. Epub 2023 Feb 15. AIDS Res Hum Retroviruses. 2023. PMID: 36416229
Immunological and virological findings in a patient with exceptional post-treatment control: a case report.
Climent N, Ambrosioni J, González T, Xufré C, Casadellà M, Noguera-Julian M, Paredes R, Plana M, Grau-Expósito J, Mallolas J, Alcamí J, Sánchez-Palomino S, Miró JM; Hospital Clínic de Barcelona PHI investigators. Climent N, et al. Lancet HIV. 2023 Jan;10(1):e42-e51. doi: 10.1016/S2352-3018(22)00302-2. Epub 2022 Oct 27. Lancet HIV. 2023. PMID: 36354046
The role of the different CD3γ domains in TCR expression and signaling.
Garcillán B, Megino RF, Herrero-Alonso M, Guardo AC, Perez-Flores V, Juraske C, Idstein V, Martin-Fernandez JM, Geisler C, Schamel WWA, Marin AV, Regueiro JR. Garcillán B, et al. Among authors: guardo ac. Front Immunol. 2022 Sep 2;13:978658. doi: 10.3389/fimmu.2022.978658. eCollection 2022. Front Immunol. 2022. PMID: 36119034 Free PMC article.
Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B.
Couto E, Diaz-Brito V, Mothe B, Guardo AC, Fernandez I, Ugarte A, Etcheverry F, Gómez CE, Esteban M, Pich J, Arnaiz JA, López Bernaldo de Quirós JC, Brander C, Plana M, García F, Leal L. Couto E, et al. Among authors: guardo ac. Vaccines (Basel). 2019 Nov 7;7(4):178. doi: 10.3390/vaccines7040178. Vaccines (Basel). 2019. PMID: 31703287 Free PMC article.
Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection.
Leal L, Guardo AC, Morón-López S, Salgado M, Mothe B, Heirman C, Pannus P, Vanham G, van den Ham HJ, Gruters R, Andeweg A, Van Meirvenne S, Pich J, Arnaiz JA, Gatell JM, Brander C, Thielemans K, Martínez-Picado J, Plana M, García F; iHIVARNA consortium. Leal L, et al. Among authors: guardo ac. AIDS. 2018 Nov 13;32(17):2533-2545. doi: 10.1097/QAD.0000000000002026. AIDS. 2018. PMID: 30289805 Free PMC article. Clinical Trial.
A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.
Rojas J, Blanco JL, Sanchez-Palomino S, Marcos MA, Guardo AC, Gonzalez-Cordon A, Lonca M, Tricas A, Rodriguez A, Romero A, Miro JM, Mallolas J, Gatell JM, Plana M, Martinez E. Rojas J, et al. Among authors: guardo ac. AIDS. 2018 Jul 31;32(12):1633-1641. doi: 10.1097/QAD.0000000000001843. AIDS. 2018. PMID: 29746294 Clinical Trial.
Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, de Quirós JCLB, García F, Plana M; RISVAC02boost study. Guardo AC, et al. PLoS One. 2018 Apr 10;13(4):e0195915. doi: 10.1371/journal.pone.0195915. eCollection 2018. PLoS One. 2018. PMID: 29634751 Free PMC article.
Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, López Bernaldo de Quirós JC, García F, Plana M; RISVAC02boost study. Guardo AC, et al. PLoS One. 2017 Oct 24;12(10):e0186602. doi: 10.1371/journal.pone.0186602. eCollection 2017. PLoS One. 2017. PMID: 29065142 Free PMC article. Clinical Trial.
Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression.
Vitallé J, Zenarruzabeitia O, Terrén I, Plana M, Guardo AC, Leal L, Peña J, García F, Borrego F. Vitallé J, et al. Among authors: guardo ac. Front Immunol. 2017 Jul 21;8:836. doi: 10.3389/fimmu.2017.00836. eCollection 2017. Front Immunol. 2017. PMID: 28785262 Free PMC article.
31 results